Zacks Investment Research Downgrades NantHealth (NH) to Sell

Zacks Investment Research downgraded shares of NantHealth (NASDAQ:NH) from a hold rating to a sell rating in a research report released on Tuesday.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

Other analysts have also issued reports about the stock. ValuEngine upgraded shares of NantHealth from a hold rating to a buy rating in a report on Monday, July 2nd. BidaskClub upgraded shares of NantHealth from a hold rating to a buy rating in a report on Friday, July 6th. Finally, Canaccord Genuity reiterated a hold rating on shares of NantHealth in a research note on Tuesday, July 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. NantHealth currently has an average rating of Hold and a consensus target price of $4.31.

Shares of NH opened at $1.42 on Tuesday. The stock has a market capitalization of $171.87 million, a P/E ratio of -1.27 and a beta of -0.01. NantHealth has a 12-month low of $1.30 and a 12-month high of $4.44. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.48 and a current ratio of 1.50.

NantHealth (NASDAQ:NH) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $22.05 million for the quarter, compared to analyst estimates of $24.50 million. NantHealth had a negative net margin of 124.02% and a negative return on equity of 49.56%. Analysts expect that NantHealth will post -0.63 earnings per share for the current year.

An institutional investor recently raised its position in NantHealth stock. BlackRock Inc. grew its holdings in shares of NantHealth Inc (NASDAQ:NH) by 9.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,337,249 shares of the company’s stock after purchasing an additional 193,491 shares during the period. BlackRock Inc. owned about 2.15% of NantHealth worth $7,735,000 as of its most recent SEC filing. 5.63% of the stock is currently owned by hedge funds and other institutional investors.

NantHealth Company Profile

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

Read More: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on NantHealth (NH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply